Comparison of endoscopic treatment modalities for Barrett’s neoplasia

David, Waseem; Qumseya, Bashar J.; Qumsiyeh, Yazen; Heckman, Michael G.; Diehl, Nancy N.; Wallace, Michael B.; Raimondo, Massimo; Woodward, Timothy A.; Wolfsen, Herbert C.

doi:10.1016/j.gie.2015.03.1979

Cited by 7 publications

(4 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All studies were published between 2007 and 2015 (two studies identified as abstracts were accepted as manuscripts in 2015). 42,45 In most studies (73%, n ¼ 27), the treatment protocol included EMR in addition to RFA, which was usually performed in a separate endoscopic session. In 77% (n ¼ 28), a combination of RFA devices (focal and circumferential) was used in the treatment protocol.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Adverse Events After Radiofrequency Ablation in Patients With Barrett’s Esophagus: A Systematic Review and Meta-analysis

Qumseya

Wani

Desai

et al. 2016

Clinical Gastroenterology and Hepatology

Self Cite

144

105

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

“…Stricture formation accounted for the majority of reported adverse events at a pooled rate of 5.6% (95% CI, 4.2%-7.4%), P < .001, I 2 ¼ 78%. Perforations were reported in 4 studies, 14,21,29,30 totaling 5 patients (Table 1). Of those 5 cases, 2 perforations 14,30 were related to EMR, not RFA.…”

Section: Secondary Outcomesmentioning

confidence: 99%

Adverse Events After Radiofrequency Ablation in Patients With Barrett’s Esophagus: A Systematic Review and Meta-analysis

Qumseya

Wani

Desai

et al. 2016

Clinical Gastroenterology and Hepatology

Self Cite

144

105

View full text Add to dashboard Cite

show abstract

“…A large cohort retrospective study showed that Photofrin ® -PDT was more effective in achieving a complete response in HGD and ADC patients compared to other modalities. However, the morbidities related to Photofrin ® and the additional financial investment needed for PDT, drive clinicians to use other modalities such as RFA and EMR [ 163 ]. Recognizing the potential of PDT, it remains an active topic of research.…”

Section: Pdt In Clinical Trialsmentioning

confidence: 99%

Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions

Straten

Mashayekhi

Bruijn

et al. 2017

Cancers

845

675

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a clinically approved cancer therapy, based on a photochemical reaction between a light activatable molecule or photosensitizer, light, and molecular oxygen. When these three harmless components are present together, reactive oxygen species are formed. These can directly damage cells and/or vasculature, and induce inflammatory and immune responses. PDT is a two-stage procedure, which starts with photosensitizer administration followed by a locally directed light exposure, with the aim of confined tumor destruction. Since its regulatory approval, over 30 years ago, PDT has been the subject of numerous studies and has proven to be an effective form of cancer therapy. This review provides an overview of the clinical trials conducted over the last 10 years, illustrating how PDT is applied in the clinic today. Furthermore, examples from ongoing clinical trials and the most recent preclinical studies are presented, to show the directions, in which PDT is headed, in the near and distant future. Despite the clinical success reported, PDT is still currently underutilized in the clinic. We also discuss the factors that hamper the exploration of this effective therapy and what should be changed to render it a more effective and more widely available option for patients.

show abstract

“…The same group later published longterm follow up of their data and demonstrated that the rate of CE-HGD was maintained at 5 year follow-up (61). A newer retrospective observational study published in 2016 from a single center evaluating PDT vs. RFA + EMR vs. RFA alone in the treatment of BE showed a higher rate of CE-IM at 1 year for the PDT group (71.9%) compared to the RFA + EMR group (47.8%) and the RFA group (22.9%) (62). The main treatment-related adverse events of PDT in the esophagus include skin photosensitivity and esophageal stricture formation.…”

Section: Photodynamic Therapy (Pdt)mentioning

confidence: 95%

Barrett’s esophagus: best practices for treatment and post-treatment surveillance

Mansour

El–Serag

Anandasabapathy

2017

Ann. Cardiothorac. Surg.

View full text Add to dashboard Cite

Barrett's esophagus (BE) is a premalignant condition that increases the risk of esophageal adenocarcinoma (EAC). Significantly more common in the Western world, risk factors include increased age, male sex, white race, gastro-esophageal reflux disease (GERD), central obesity, and cigarette smoking. The rates of progression to cancer depend on the grade of Barrett's dysplasia. Screening for BE is recommended in patients with GERD and additional risk factors. Endoscopic surveillance of patients with BE likely improves overall outcomes. Advanced endoscopic imaging can help increase the efficiency of current endoscopic surveillance.Endoscopic therapy is safe and effective for the treatment of dysplastic BE and intramucosal EAC, but ongoing surveillance following treatment is necessary. This review will cover screening, surveillance, advanced imaging, chemoprevention, endoscopic treatment, and post-treatment surveillance of BE.

show abstract

Comparison of endoscopic treatment modalities for Barrett’s neoplasia

Cited by 7 publications

References 47 publications

Adverse Events After Radiofrequency Ablation in Patients With Barrett’s Esophagus: A Systematic Review and Meta-analysis

Adverse Events After Radiofrequency Ablation in Patients With Barrett’s Esophagus: A Systematic Review and Meta-analysis

Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions

Barrett’s esophagus: best practices for treatment and post-treatment surveillance

Contact Info

Product

Resources

About